[Efficacy and tolerance of veralipride in the treatment of flushing in the menopause. A multicenter study].
An open ended multicentric study has enabled to evaluate the efficacy and the tolerance of veralipride on sudden flushes and associated disorders of menopause. It included 166 women (125 in natural menopause) between the ages of 32 and 68 (mean age: 52). Veralipride was administered at a dose of 100 mg/day (1 capsule) for three sequences of 20 days separated by 10 days without treatment. The results were observed on 138 cases (28 withdrawals) at DO, D3M (after 3 months of treatment), D6M (three months after interruption of the treatment). The results were considered as excellent or good in 89.9 per cent of the cases at D3M. Three months later, the results were still excellent or good in 64.5 per cent of the cases. The self evaluation by the patients gave similar results: 91.1 per cent of favorable opinions at D3M and 80.7 per cent at D6M. The systolic and diastolic blood pressure did not vary during the observation period. These results confirm those obtained in previous studies.
D000368:Aged; D000369:Aged, 80 and over; D002979:Climacteric / Q000187:drug effects*; D002986:Clinical Trials as Topic; D005260:Female; D006801:Humans; D008875:Middle Aged; D013469:Sulpiride / Q000031:analogs & derivatives* / Q000627:therapeutic use
D013469:Sulpiride; C027429:veralipride
Efficacité et tolérance du véralipride dans le traitement des bouffées de chaleur de la ménopause. Etude multicentrique.